100 Active Studies

Heart Attack Clinical Trials Near You

Find 100 actively recruiting heart attack research studies near you. Connect with study sites, check eligibility, and explore new treatment options.

100
Active Trials
294+
Locations
84,321
Participants Needed

Recruiting Studies

RecruitingNCT05754957

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of car...

10 locations(Alexander City, Birmingham, Birmingham)
16,000 participants
Janssen Research & Development, LLC
View Study Details
RecruitingNCT06118281

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, the...

10 locations(Alexander City, Birmingham, Birmingham)
10,000 participants
Novo Nordisk A/S
View Study Details
RecruitingNCT04606264

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

This REMAP Periop ERP domain study falls under the Periop Core Protocol, which compares the different recommended strategies for enhancing recovery through the use of various standard of care treatmen...

3 locations(Pittsburgh, Pittsburgh, Pittsburgh)
2,500 participants
Jennifer Holder-Murray
View Study Details
RecruitingNCT04649242

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents....

10 locations(Birmingham, Scottsdale, Tempe)
2,100 participants
Pfizer
View Study Details
RecruitingNCT03013998

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)."...

10 locations(Phoenix, Los Angeles, San Francisco)
2,000 participants
Beat AML, LLC
View Study Details
RecruitingNCT05918861

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will prov...

10 locations(Alexander City, Birmingham, Fairhope)
2,000 participants
DalCor Pharmaceuticals
View Study Details
RecruitingNCT04396236

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits....

10 locations(Birmingham, Huntsville, Phoenix)
1,633 participants
Eli Lilly and Company
View Study Details
RecruitingNCT06972056

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive me...

7 locations(Flagstaff, Phoenix, Los Angeles)
1,335 participants
Mayo Clinic
View Study Details
RecruitingNCT06136559

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma...

10 locations(Mobile, Prescott, Berkeley)
1,200 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT05125302

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Mig...

10 locations(Huntsville, Saraland, Phoenix)
1,059 participants
AbbVie
View Study Details
RecruitingNCT05535946

ABTECT - Maintenance

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with m...

10 locations(Birmingham, Dothan, Guntersville)
1,050 participants
Abivax S.A.
View Study Details
RecruitingNCT05843643

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult...

10 locations(Chandler, Flagstaff, Gilbert)
1,000 participants
AbbVie
View Study Details
RecruitingNCT04396574

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will la...

10 locations(Birmingham, Huntsville, Phoenix)
1,000 participants
Eli Lilly and Company
View Study Details
RecruitingNCT07018700

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine d...

8 locations(Phoenix, Los Angeles, Decatur)
990 participants
Merz Therapeutics GmbH
View Study Details
RecruitingNCT04726241

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from pati...

10 locations(Birmingham, Mobile, Anchorage)
960 participants
PedAL BCU, LLC
View Study Details
RecruitingNCT06289673

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The ter...

3 locations(San Diego, Tulsa, Memphis)
850 participants
St. Jude Children's Research Hospital
View Study Details
RecruitingNCT06323928

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to preve...

10 locations(Hoover, Carlsbad, Fullerton)
845 participants
H. Lundbeck A/S
View Study Details
RecruitingNCT03037164

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

Stage A: To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBC...

10 locations(Phoenix, New Haven, Jacksonville)
800 participants
Cerus Corporation
View Study Details
RecruitingNCT05681351

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG....

10 locations(Los Angeles, San Diego, Tarzana)
800 participants
Ionis Pharmaceuticals, Inc.
View Study Details
RecruitingNCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....

10 locations(Miami, Sarasota, Atlanta)
787 participants
Eli Lilly and Company
View Study Details
RecruitingNCT07018713

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine da...

9 locations(Phoenix, Los Angeles, Decatur)
780 participants
Merz Therapeutics GmbH
View Study Details
RecruitingNCT06990867

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question th...

10 locations(Chicago, Baltimore, Tulsa)
740 participants
Corxel Pharmaceuticals
View Study Details
RecruitingNCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

10 locations(La Jolla, Los Angeles, Sacramento)
727 participants
Immunocore Ltd
View Study Details
RecruitingNCT06641466

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience ...

10 locations(Canoga Park, Colton, Walnut Creek)
723 participants
Pfizer
View Study Details
RecruitingNCT05947851

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypothese...

10 locations(Springdale, Long Beach, Pembroke Pines)
720 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT06047444

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe thr...

10 locations(Birmingham, Phoenix, Scottsdale)
720 participants
Ipsen
View Study Details
RecruitingNCT04638647

Secukinumab Open Label Roll-over Extension Protocol

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment w...

10 locations(Fullerton, La Mesa, San Leandro)
715 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT06047457

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine. A migraine is a headache with severe th...

10 locations(Birmingham, Phoenix, Scottsdale)
714 participants
Ipsen
View Study Details
RecruitingNCT06578247

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (I...

10 locations(Goodyear, Phoenix, Tucson)
700 participants
Daiichi Sankyo
View Study Details
RecruitingNCT01804686

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolle...

10 locations(Duarte, La Jolla, Los Angeles)
700 participants
Janssen Research & Development, LLC
View Study Details
RecruitingNCT04064060

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the t...

10 locations(Los Angeles, Oakland, Stanford)
665 participants
Celgene
View Study Details
RecruitingNCT05254743

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment...

10 locations(Anaheim, Cerritos, Palo Alto)
662 participants
Loxo Oncology, Inc.
View Study Details
RecruitingNCT06073821

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)...

10 locations(Anchorage, Duarte, La Jolla)
652 participants
BeiGene
View Study Details
RecruitingNCT06625060

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and s...

10 locations(Chandler, Carlsbad, Encino)
641 participants
Ipsen
View Study Details
RecruitingNCT05156398

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine....

10 locations(Fort Smith, Hawthorne, La Mesa)
640 participants
Pfizer
View Study Details
RecruitingNCT06943872

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia...

10 locations(Orange, Palo Alto, San Diego)
630 participants
BeiGene
View Study Details
RecruitingNCT06852222

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukem...

10 locations(Little Rock, Orlando, Tampa)
600 participants
Janssen Research & Development, LLC
View Study Details
RecruitingNCT05164172

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine....

10 locations(Stamford, Gulf Breeze, Hialeah)
600 participants
H. Lundbeck A/S
View Study Details
RecruitingNCT04743141

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age)....

10 locations(Scottsdale, Tempe, Anaheim)
600 participants
Pfizer
View Study Details
RecruitingNCT06615050

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning ...

10 locations(Palo Alto, Miami, Tampa)
572 participants
Incyte Corporation
View Study Details
RecruitingNCT06133972

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of t...

10 locations(Anniston, La Palma, Westlake Village)
550 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT04895241

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active...

10 locations(Homewood, Beverly Hills, Los Angeles)
540 participants
Biogen
View Study Details
RecruitingNCT04961567

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active...

10 locations(Birmingham, Glendale, Huntington Beach)
540 participants
Biogen
View Study Details
RecruitingNCT04910685

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants w...

10 locations(Birmingham, Palo Alto, Boston)
534 participants
Blueprint Medicines Corporation
View Study Details
RecruitingNCT05620407

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population....

10 locations(Searcy, La Jolla, La Mesa)
490 participants
Bristol-Myers Squibb
View Study Details
RecruitingNCT05617677

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population....

10 locations(Birmingham, Phoenix, Phoenix)
490 participants
Bristol-Myers Squibb
View Study Details
RecruitingNCT04546399

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come ...

10 locations(Birmingham, Mobile, Anchorage)
461 participants
National Cancer Institute (NCI)
View Study Details
RecruitingNCT06417775

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, o...

10 locations(Birmingham, Huntsville, Chandler)
450 participants
AbbVie
View Study Details
RecruitingNCT06617325

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of mo...

10 locations(Avondale, Chandler, Gilbert)
450 participants
UCB Biopharma SRL
View Study Details
RecruitingNCT05711394

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other sy...

10 locations(Huntsville, Little Rock, Little Rock)
450 participants
AbbVie
View Study Details
RecruitingNCT05602194

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Aspara...

10 locations(Birmingham, Anchorage, Kingman)
440 participants
Children's Oncology Group
View Study Details
RecruitingNCT04623541

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refract...

10 locations(Birmingham, California City, Duarte)
424 participants
Genmab
View Study Details
RecruitingNCT06810505

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to...

10 locations(Huntsville, Little Rock, Little Rock)
420 participants
AbbVie
View Study Details
RecruitingNCT06033599

Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement

The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake...

2 locations(New Brunswick, Salt Lake City)
420 participants
Rutgers, The State University of New Jersey
View Study Details
RecruitingNCT05672576

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer ar...

10 locations(Tucson, La Jolla, Northridge)
420 participants
Viatris Innovation GmbH
View Study Details
RecruitingNCT05648500

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms. The main questions it aims to answer a...

10 locations(Fullerton, Huntington Park, Aurora)
420 participants
Viatris Innovation GmbH
View Study Details
RecruitingNCT04065399

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled...

10 locations(Duarte, Los Angeles, Palo Alto)
413 participants
Syndax Pharmaceuticals
View Study Details
RecruitingNCT05639114

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC)...

10 locations(Tucson, Burbank, La Jolla)
406 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT07000136

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and L...

10 locations(Chula Vista, Garden Grove, Lake Forest)
405 participants
AstraZeneca
View Study Details
RecruitingNCT06351631

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bome...

10 locations(Ann Arbor, Durham, Columbus)
400 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT06001918

Nectero EAST System Clinical Study

The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dos...

10 locations(Scottsdale, San Francisco, Aurora)
400 participants
Nectero Medical, Inc.
View Study Details
RecruitingNCT04811560

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 ...

10 locations(Duarte, Orange, San Francisco)
400 participants
Janssen Research & Development, LLC
View Study Details
RecruitingNCT05645107

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections p...

10 locations(St. Petersburg, Greenville, Morrisville)
386 participants
Grifols Therapeutics LLC
View Study Details
RecruitingNCT05429632

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial....

10 locations(Birmingham, Gilbert, Duarte)
366 participants
Priothera SAS
View Study Details
RecruitingNCT04278768

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Sy...

10 locations(Tampa, Atlanta, Chicago)
366 participants
Curis, Inc.
View Study Details
RecruitingNCT04988555

A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in adult patients with acute leukemia....

10 locations(Newport Beach, Denver, Miami)
362 participants
Sumitomo Pharma America, Inc.
View Study Details
RecruitingNCT07102459

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

The goal of this clinical trial is to learn if LTG-001 works to treat post-operative / acute pain after an abdominoplasty procedure. It will also learn more information on the safety of LTG-001. The ...

4 locations(Atlanta, Houston, San Antonio)
360 participants
Latigo Biotherapeutics
View Study Details
RecruitingNCT06396247

Impact of Brief Daily Functional Resistance Training on Lower Extremity Physical Performance

In this study, we will randomly assign 360 older adults to 12 months of 5 minutes per day of functional resistance training or to a delayed treatment control condition, and measure the impact of the t...

2 locations(Hershey, Pittsburgh)
360 participants
Milton S. Hershey Medical Center
View Study Details
RecruitingNCT06233799

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing...

10 locations(Little Rock, Los Angeles, San Diego)
360 participants
National Institute on Drug Abuse (NIDA)
View Study Details
RecruitingNCT06456567

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE....

4 locations(Hemet, Menifee, Rockford)
350 participants
RemeGen Co., Ltd.
View Study Details
RecruitingNCT06411249

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ...

10 locations(Anniston, Flagstaff, Mesa)
350 participants
GlaxoSmithKline
View Study Details
RecruitingNCT06139328

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack. T...

10 locations(Tucson, Covina, Golden)
350 participants
Boehringer Ingelheim
View Study Details
RecruitingNCT04530565

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-...

10 locations(Birmingham, Anchorage, Anchorage)
348 participants
National Cancer Institute (NCI)
View Study Details
RecruitingNCT04877522

Asciminib Roll-over Study

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment...

10 locations(Ann Arbor, New York, Portland)
347 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT05554406

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with...

10 locations(Birmingham, Phoenix, Tucson)
335 participants
National Cancer Institute (NCI)
View Study Details
RecruitingNCT03432286

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is t...

10 locations(Huntsville, Phoenix, Phoenix)
325 participants
Eli Lilly and Company
View Study Details
RecruitingNCT05925634

Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial

The goal of this clinical trial is to compare two types of exercise prescriptions in cardiac rehabilitation eligible older adults (60 years or older) with heart disease. The investigators found in a s...

2 locations(Springfield, Detroit)
320 participants
Baystate Medical Center
View Study Details
RecruitingNCT05963074

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reacti...

10 locations(Cerritos, Los Alamitos, San Luis Obispo)
320 participants
Janssen Research & Development, LLC
View Study Details
RecruitingNCT03331198

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to de...

10 locations(Birmingham, Birmingham, Gilbert)
320 participants
Juno Therapeutics, a Subsidiary of Celgene
View Study Details
RecruitingNCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...

6 locations(Scottsdale, Denver, New Haven)
316 participants
Simcha IL-18, Inc.
View Study Details
RecruitingNCT05897320

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants....

10 locations(Stamford, Gulf Breeze, Hialeah)
315 participants
H. Lundbeck A/S
View Study Details
RecruitingNCT07122193

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The study will be conducted in two periods: ...

10 locations(Santa Monica, Vista, Greenwood Village)
300 participants
Merz North America, Inc.
View Study Details
RecruitingNCT06456346

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreduct...

10 locations(Glendale, Palo Alto, Golden)
300 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT05462704

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

Double blind, placebo controlled, multicenter randomized trial in pregnant women in the U.S. (N=300) to test the central hypothesis that IV iron in pregnant women with IDA (Hb\<11 g/dL and ferritin\<3...

8 locations(Birmingham, Miami, Ann Arbor)
300 participants
Women and Infants Hospital of Rhode Island
View Study Details
RecruitingNCT05948566

Strategy for Improving Stroke Treatment Response

SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alp...

10 locations(Birmingham, Phoenix, Phoenix)
300 participants
Translational Sciences, Inc.
View Study Details
RecruitingNCT05238519

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to recei...

2 locations(Duluth, Duluth)
300 participants
Essentia Health
View Study Details
RecruitingNCT06079879

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate re...

10 locations(Glendale, Stanford, Torrance)
300 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT05878717

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lun...

10 locations(Phoenix, Scottsdale, Scottsdale)
300 participants
GlaxoSmithKline
View Study Details
RecruitingNCT04616326

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is t...

10 locations(Huntsville, Phoenix, Phoenix)
300 participants
Eli Lilly and Company
View Study Details
RecruitingNCT04005378

Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs

Maintaining treatment engagement is critical for first episode psychosis patients to experience gains possible with coordinated specialty care (CSC). This study is designed to identify CSC participant...

3 locations(Lauderdale Lakes, Grand Rapids, Kalamazoo)
300 participants
Northwell Health
View Study Details
RecruitingNCT00775476

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack ...

8 locations(Los Angeles, New Haven, New York)
290 participants
State University of New York - Upstate Medical University
View Study Details
RecruitingNCT04965675

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine....

10 locations(New Haven, Stamford, Washington D.C.)
285 participants
H. Lundbeck A/S
View Study Details
RecruitingNCT04994717

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free s...

10 locations(Duarte, Orange, San Francisco)
284 participants
Amgen
View Study Details
RecruitingNCT04521231

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leu...

10 locations(Duarte, New York, Houston)
281 participants
Amgen
View Study Details
RecruitingNCT06876662

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-...

10 locations(Miami, Sarasota, Atlanta)
279 participants
Eli Lilly and Company
View Study Details
RecruitingNCT06820177

Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes

Although procedural abortion in the second trimester is extremely safe, hemorrhage is one of the leading causes of morbidity and mortality. Tranexamic acid (TXA) is used commonly in obstetrics to prev...

2 locations(San Diego, San Diego)
276 participants
University of California, San Diego
View Study Details
RecruitingNCT06933472

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lo...

10 locations(Lone Tree, Orange, Fort Myers)
264 participants
Alebund Pharmaceuticals
View Study Details
RecruitingNCT04067336

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Pha...

10 locations(Gilbert, Phoenix, Los Angeles)
263 participants
Kura Oncology, Inc.
View Study Details
RecruitingNCT05436418

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers. Somet...

2 locations(Duarte, Bethesda)
260 participants
National Cancer Institute (NCI)
View Study Details
RecruitingNCT06846671

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venet...

10 locations(Jonesboro, Los Angeles, Whittier)
250 participants
BeiGene
View Study Details

Top Cities for Heart Attack Clinical Trials

Heart Attack clinical trials are recruiting across 294 cities. Here are the cities with the most active studies:

About Heart Attack

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

Clinical trials are advancing new treatments for heart attack. Currently, 100 studies are recruiting a combined 84,321 participants across the United States. Research is being conducted by 61 organizations including Janssen Research & Development, LLC, Novo Nordisk A/S, Jennifer Holder-Murray and 58 others.

2026 Heart Attack Research Landscape

As of March 2026, the heart attack clinical trial landscape includes 100 actively recruiting studies across 294 cities in the United States. These studies are collectively seeking 84,321 participants, with an average enrollment target of 843 per study.

Research is being led by 61 different organizations, including Janssen Research & Development, LLC, Novo Nordisk A/S, Jennifer Holder-Murray, Pfizer, Beat AML, LLC, and 56 others. The large number of sponsors reflects significant research interest and investment in heart attack treatment advancement.

Geographically, heart attack trials are most concentrated in Los Angeles, California (36 trials); Phoenix, Arizona (31 trials); Birmingham, Alabama (26 trials); Tucson, Arizona (22 trials); Little Rock, Arkansas (19 trials) and 7 other cities.

Featured Heart Attack Studies

Highlighted recruiting studies for heart attack, selected by enrollment size and research scope.

RecruitingNCT05754957

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).

Sponsor: Janssen Research & Development, LLC· 16,000 participants· 10 locations (Alexander City, Birmingham, Birmingham, Mobile)
View full study details →
RecruitingNCT06118281

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants ge...

Sponsor: Novo Nordisk A/S· 10,000 participants· 10 locations (Alexander City, Birmingham, Birmingham, Fairhope)
View full study details →
RecruitingNCT04606264

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

This REMAP Periop ERP domain study falls under the Periop Core Protocol, which compares the different recommended strategies for enhancing recovery through the use of various standard of care treatments before, during and after surgery in all patients with elective surgical encounters at UPMC who meet eligibility criteria. The ERP domain seeks to enhance recovery by optimizing strategies of perio...

Sponsor: Jennifer Holder-Murray· 2,500 participants· 3 locations (Pittsburgh, Pittsburgh, Pittsburgh)
View full study details →

Frequently Asked Questions About Heart Attack Clinical Trials

Are there heart attack clinical trials near me?

Yes, there are 100 heart attack clinical trials currently recruiting across 294+ cities in the United States, including Los Angeles, California; Phoenix, Arizona; Birmingham, Alabama. Browse the studies above to find one at a location convenient for you.

How do I join a heart attack clinical trial?

To join a heart attack clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.

Are heart attack clinical trials free?

Yes, participation in heart attack clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.

What types of heart attack treatments are being studied?

Current heart attack clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 61 research organizations.

Is it safe to participate in heart attack clinical trials?

Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.

Data updated March 2, 2026 from ClinicalTrials.gov

About This Data

Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.

Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.

Page reviewed by the HelloStudys Research Team · Last updated March 2, 2026 · Data from ClinicalTrials.gov